

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Winchester Cardiology & Vascular Medicine, P.C.	In accordance with letter dated January 07, 2020.	4. Expiration Date: October 31, 2034	
2. Cardiovascular Imaging Center 190 Campus Boulevard, Suite 201 Winchester, VA 22601	3. License number: 47-31390-01 is amended in its entirety to read as follows:	5. Docket No.: 030-38177 Reference No.:	
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.200	7. Chemical and/or physical form A. Any	8. Maximum amount that licensee may possess at any one time under this license A. As Needed	9. Authorized use A. For use in imaging and localization studies permitted by 10 CFR 35.200.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:
- A. 1000 Tavern Road, Suite 200, Martinsburg, West Virginia, 25401
 - B. 120 Campus Drive, Suite 201, Martinsburg, West Virginia, 25404
11. The Radiation Safety Officer (RSO) for this license is Michael W. Lairmore, M.S.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

47-31390-01

Docket or Reference Number

030-38177

Amendment No. 6

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized UsersMaterial and Use

Saif Al-Najafi, M.D.

10 CFR 35.200

Brandon Barrett, M.D.

10 CFR 35.200

James Dixon Brown, M.D.

10 CFR 35.200

Jason T. Call, M.D.

10 CFR 35.200

Anne Kanderian Kassira, M.D.

10 CFR 35.200

Manish Lakhani, M.D.

10 CFR 35.200

Trisha B. Nashed, M.D.

10 CFR 35.200

Daniel Reese, M.D.

10 CFR 35.200

Jeffrey Skiles, M.D.

10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

47-31390-01

Docket or Reference Number

030-38177

Amendment No. 6

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated July 29, 2019 [ML19226A119]
- B. Letter dated August 27, 2019 [ML19248C755]
- C. Letter dated January 7, 2020 [ML20034D963]
- D. Letter dated February 13, 2020 [ML20045D282]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 20, 2020

By: _____

Penny Lanzisera
Region 1